跳至主要内容
临床试验/NCT00955942
NCT00955942终止1 期

A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy

Abramson Cancer Center at Penn Medicine2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2007年12月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
入组人数
48
试验地点
2
主要终点
Toxicity and tolerability of dietary FS supplementation during chemoradiotherapy

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help protect normal cells from the side effects of radiation therapy.

PURPOSE: This randomized phase I trial is studying the side effects of flaxseed supplement in treating patients with locally advanced or metastatic non-small cell lung cancer undergoing chemotherapy and radiation therapy.

详细描述

OBJECTIVES:

Primary

  • To assess the feasibility of dietary flaxseed (FS) supplementation in patients undergoing definitive chemoradiotherapy for locally advanced or metastatic non-small cell lung cancer.
  • To collect toxicity and tolerability data on dietary FS supplementation during definitive chemoradiotherapy.

Secondary

  • To validate urinary and serum markers of oxidative stress and FS lignan levels as surrogates of the bioavailability of FS in these patients.
  • To determine if a dose response to daily ingestion of 20 g or 40 g of FS can be observed in plasma lignan levels and urinary markers of oxidative stress.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Toxicity and tolerability of dietary FS supplementation during chemoradiotherapy

Feasibility of dietary flaxseed (FS) supplementation

次要结局

  • Measures of biomarkers of oxidative stress
  • Measures of serum levels of FS metabolites

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Flaxseed Supplement in Treating Patients With... | 临床试验